AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 152 min read$ONC

Rosenberg Aaron sold $163K of ONC

Rosenberg Aaron (Chief Financial Officer) sold 631 shares of BeOne Medicines Ltd. (ONC) at $257.74 ($0.16M total) on 2026-06-11.

Original reporting
SEC EDGAR · Rosenberg Aaron
Published Jun 15, 2026, 9:55 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 15, 2026, 9:56 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ONC
Neutral
low confidence
Mentioned
$ONC
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ONCNeutralLow
01

Why it matters

The newest fact is the CFO’s open-market sale and resulting 0-share direct holding; there is no accompanying corporate event in the text.

02

Market read

This provides a fresh, company-specific insider activity datapoint that may slightly influence sentiment but lacks fundamental triggers in the provided text.

03

What to watch

Form 4 sales often do not imply bearish expectations; traders should check for other concurrent insider buys/sales and any upcoming company catalysts (trials, financing, guidance) not present in this text.

Relevance 4/10Novelty 8/10Timing: Filed on 2026-06-15; sale dated 2026-06-11.

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for BeOne Medicines Ltd. (ONC).

Company-level read

Ticker impact

$ONCNeutralLow confidence
Context

SEC Form 4 shows ONC CFO Aaron Rosenberg sold 631 shares in an open-market transaction for about $162.6K, leaving 0 shares.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than a re-rating catalyst.

Evidence & confidence

The filing is a routine Form 4 insider sale with no 10b5-1 plan disclosed and no accompanying company-specific operational or financial news.

Market effects

Sector

No sector-level read-across; this is a single-company insider transaction.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be unrelated to fundamentals (tax/liquidity/portfolio rebalancing), especially given the small share count and lack of disclosed 10b5-1 plan details.

Key entities

  • issuer
    BeOne Medicines Ltd.

    Subject of the SEC Form 4 insider transaction disclosure (ONC).

  • insider
    Aaron Rosenberg

    Chief Financial Officer who sold 631 shares in an open-market transaction.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ONC insider trading history →

Related articles

SEP 1
$ONCHighAI 9/10

FDA Approval Marks A Turning Point For BeOne Medicines (ONC)

BeOne Medicines (ONC) announced FDA approval for TEVIMBRA in combination with ZIIHERA and chemotherapy for HER2-positive gastroesophageal adenocarcinoma. The approval is based on Phase 3 trial data showing a median survival of 26.4 months. The company reported Q2 2026 revenue of $1.7 billion, up 30% YoY, and raised full-year revenue guidance to $6.6B-$6.8B. However, a Phase 3 study for zanubrutinib-sonrotoclax combination did not meet its primary endpoint.

yahoo.com2 min
SEP 1
$ALCMedAI 8/10

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

President Trump's administration signed drug-pricing agreements with nine mid-sized pharmaceutical companies, including Astellas Pharma, Teva, and UCB, to lower U.S. drug prices under the MFN proposal. Companies agreed to reduce prices and invest $19.6B in U.S. manufacturing, with some contributing APIs to a government reserve. The deals cover 89% of the branded drug market, expanding beyond initial Big Pharma focus.

tradingview.com3 min
SEP 1
$ALCLow

Trump Expands Drug Pricing Agreements With 9 Drugmakers— RFK Jr. Says President Called ‘Every Hour’ to En

President Trump announced drug pricing agreements with nine pharmaceutical companies, including Alcon (ALC), BeOne (ONC), BridgeBio (BBIO), and Teva (TEVA). The deals require discounts on outpatient drugs for Medicaid and $19.6B in U.S. manufacturing investments. This expands the total to 26 companies, covering 90% of the U.S. market. The White House estimates $529B in savings over a decade.

benzinga.com2 min
AUG 31
$ONCHighAI 8/10

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer

BeOne Medicines reported positive Phase 3 trial results for ZIIHERA (zanidatamab) plus chemotherapy, with and without TEVIMBRA (tislelizumab), in HER2+ gastroesophageal cancer. The study met its primary endpoint, showing statistically significant overall survival benefits. The FDA recently approved these regimens for first-line treatment. BeOne has rights to ZIIHERA in Asia, Australia, and New Zealand.

leaderpost.com2 min